70 billion peptide drug market, European API stocking!

Guide: Huiling Pharmaceutical Peptide Pharmaceutical Syds Supplier - Provides the same API originally researchedIn the past decade, the domestic polypeptide drug market has grown at a "rocket speed" from doubling the annual market capacity from RMB 100 million to RMB 100 million; The market growth rate of polypeptide drugs is much higher than that of chemical and biological drugsBut this is only the initial phase of nearly three years and even the next few years with the global polypeptide drugs in the heavy varieties (e.ggratiere, ether and liraglutide, etc.) patent has expired is the golden age of domestic peptide drugsA group of domestic enterprises with the ability of chemical synthesis polypeptide drugs to the rapid rise of Hanyu Pharmaceuticals, Shutai God, Haipuri, Haiwang Biological, Yuheng Pharmaceuticals and other representatives of a few large-scale production capacity of pharmaceutical enterprises began to emergeThis is far from enough to satisfy the demand supply side to take over the absolute market advantage and therefore there are many eager candidatesHowever, entering the peptide industry first faced technical barriers dozens of steps or even hundreds of steps of chemical reactions and cumbersome high-efficiency liquid phase purification technology; Some people are looking forward to the situationEurope and the United States peptide industry leader at this time almost with a full range of products to pour homeThe peptide production base was established in Malmo, Sweden, in the year, and the brother company of Huiling, which has become an independent production company in response to market demand, focuses on the development and manufacture of pharmaceutical peptide contracts ()Globally, more than one peptide drug has been listed among the API supplies fromA fully automated production site (in Europe, in the United States, in India) has world-class equipment and production levels supporting the super-annual production capacity of API and metric tons of intermediates(Large production base) into the Chinese market two leading api: cabemymysin and tripressurize has been the first to complete the record state"The remaining near varieties have been lined up to launch a chargeAce varieties of bright pririn, quprilin, octreotide, growth inhibitors belong to the domestic sales of billions of varieties; More coveted somarutide, known as "the world's best agonisant" for dramatically improving blood sugar levels in people with type diabetes, is expected to significantly reduce significant cardiovascular risk in the annual global sales of $100 millionThe year's peptide market performance makes it one of the world's largest contract development and manufacturers of pharmaceutical peptidesThe technical needs for large and small projects can be flexibly matched with a wealth of regulatory review experience sourcing production and amplification technologies, both in partnership with small start-up biotech companies and large pharmaceutical companies to meet the needs of customers at all stagesEntering the Chinese market by an overwhelming margin is a shock to another or an opportunity for anotherThe support of model products and research and development technologies (contract research organizations) and (contract production organizations) provides more possibilities for Chinese pharmaceutical companies preparing to break into the peptide industryAs a guide into China, Yu Rui Pharma has done in-depth research on its products to carry out on-site assessment of its production base to confirm that its from grams to 100 kg class of body volume can provide a balance between production scale and cost optimization is an ideal partner to recommendThe golden age of the peptide industry is not to be missedFor more information about this supplier, please contact: WeChat Public Number: Pharmaceutical Spring and Autumn or Miss Zhuang.